Clearpoint Neuro Stock Today
| CLPT Stock | USD 11.09 0.13 1.19% |
Performance0 of 100
| Odds Of DistressLess than 14
|
Clearpoint Neuro is selling for under 11.09 as of the 22nd of November 2024; that is 1.19 percent increase since the beginning of the trading day. The stock's last reported lowest price was 10.85. Clearpoint Neuro has less than a 14 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Clearpoint Neuro are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 12th of February 2020 | Category Healthcare | Classification Health Care |
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Clearpoint Neuro operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 27.58 M outstanding shares of which 687.56 K shares are currently shorted by private and institutional investors with about 3.36 trading days to cover. More on Clearpoint Neuro
Moving against Clearpoint Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Clearpoint Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Joseph Burnett | ||||
| Old Name | Collplant Holdings Ltd | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsClearpoint Neuro can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Clearpoint Neuro's financial leverage. It provides some insight into what part of Clearpoint Neuro's total assets is financed by creditors.
| |||||
Clearpoint Neuro (CLPT) is traded on NASDAQ Exchange in USA. It is located in 120 S. Sierra Avenue, Solana Beach, CA, United States, 92075 and employs 107 people. Clearpoint Neuro is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 305.91 M. Clearpoint Neuro conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 27.58 M outstanding shares of which 687.56 K shares are currently shorted by private and institutional investors with about 3.36 trading days to cover.
Clearpoint Neuro currently holds about 45.14 M in cash with (13.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84.
Check Clearpoint Neuro Probability Of Bankruptcy
Ownership AllocationClearpoint Neuro holds a total of 27.58 Million outstanding shares. 30% of Clearpoint Neuro outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Clearpoint Ownership Details
Clearpoint Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Legato Capital Management Llc | 2024-09-30 | 159 K | |
| Lane Generational Llc | 2024-09-30 | 157.7 K | |
| Jane Street Group Llc | 2024-06-30 | 144.1 K | |
| Parsons Capital Management Inc | 2024-09-30 | 139 K | |
| State Street Corp | 2024-06-30 | 129.5 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 126.6 K | |
| Squarepoint Ops Llc | 2024-06-30 | 101.8 K | |
| Y-intercept (hong Kong) Ltd | 2024-06-30 | 79.7 K | |
| D. E. Shaw & Co Lp | 2024-06-30 | 79 K | |
| Vanguard Group Inc | 2024-09-30 | 1.2 M | |
| Millennium Management Llc | 2024-06-30 | 465.5 K |
Clearpoint Neuro Historical Income Statement
Clearpoint Stock Against Markets
Clearpoint Neuro Corporate Management
| Mazin Sabra | Chief Officer | Profile | |
| Danilo DAlessandro | Chief Officer | Profile | |
| Ellisa JD | General Secretary | Profile | |
| Ellisa Cholapranee | General Secretary | Profile | |
| Jeremy Stigall | Executive Delivery | Profile | |
| Jacqueline Keller | Vice Marketing | Profile |
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.